Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
July 10, 2014
LONDON, 2 June, 2014 — Oxford BioMedica plc, a Main Market listed gene based biopharmaceutical company, announced that it intends to raise gross proceeds of up to £25.7 million through a fundraising by means of a placing and subscriptions and an open offer. Covington & Burling advised the company on the transaction. The proceeds of the fundraising will be used to continue to develop Oxford BioMedica’s business based on its LentiVector® platform, in particular to build on its growing ophthalmology portfolio. John Dawson, Chief Executive Officer of Oxford BioMedica, commented: “This successful fundraise is a testament to our leading pipeline and development and manufacturing capabilities around our LentiVector® technology. There is now broad recognition of the growing trend within the gene and cell therapy sector and it is our focus to build Oxford BioMedica into a global leader in this field. The support of our existing and new shareholders in this fundraising brings us the financial stability to now drive significant value for the future.” The Covington team was led by partner Natalie Walter, and included associates Sarah Hoult and Kate Milson. Partner Kristian Wiggert advised on US aspects of the transaction.